3-Methyladenine (3-MA)

For research use only.

Catalog No.S2767 Synonyms: NSC 66389

477 publications

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

Size Price Stock Quantity  
USD 70 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's 3-Methyladenine (3-MA) has been cited by 477 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D M37nXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXezcW0> M2rOOlJp M1PFXGROW09? M{nH[JJm\HWlZYOg[5Jwf3SqIHnubIljcXSxcomg[YZn\WO2IH;mJGJFVUN? MmDHNlU4OTZ3NkG=
A549  MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nHU|NuVQ>? MVqybC=> M4HtZ2ROW09? MYTy[YR2[2W|IHfyc5d1cCCrbnjpZol1d3K7IHXm[oVkfCCxZjDCSG1E MlHqNlU4OTZ3NkG=
95D MWLBdI9xfG:|aYOgRZN{[Xl? NIrNbHk2dU1? MnXmNog> NF\IdlVFVVOR M{\nfIlvcGmkaYTzJGJFVUNvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aB?= NXPBXZFmOjV5MU[1OlE>
A549  M1HaSmFxd3C2b4Ppd{BCe3OjeR?= NUnzXo0zPW2P M{XwNFJp MoC1SG1UVw>? M{PvUYlvcGmkaYTzJGJFVUNvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aB?= NVH5ZVVzOjV5MU[1OlE>
NBL-W-S  MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjQRpdrOW2P NEnhdIY3cA>? M1\rRYVvcGGwY3XzJGdCVlRvNkGgeI95cWOrdIm= M1GwPVI2OzJ|MkKy
NBL-W-S  NFrFVIJCeG:ydH;zbZMhSXO|YYm= MWmxcW0> NIrXUYY3cA>? M3zRcolv[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JGdCVlRvNkG= M1Xid|I2OzJ|MkKy
A2780cp  MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOxcW0> NEX5PZUycA>? NUToOmhEcW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? MnnHNlU{OjJ4OUS=
A549  MUTGeY5kfGmxbjDBd5NigQ>? MWW1cW0> NWnzSXBCOmh? NIPoXW1{fXCycnXzd4V{KFOSQzDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCOQ{OtTWk> M4\4RlI2Ojh3NkK4
H157 M2HifWZ2dmO2aX;uJGF{e2G7 NYq1bmJ2PW2P NV[xXGV[Omh? MV3zeZBxemW|c3XzJHNRSyCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBNSzNvSVm= M2TLOlI2Ojh3NkK4
MDR M4\xXGFxd3C2b4Ppd{BCe3OjeR?= NV;VfmpTOTCvTR?= MnK0Oog> M1zRfpN1emWwZ4To[Y5{KHSqZTDwc5dmeiCxZjDhcpRq[2GwY3XyJIRzfWe| MXKyOVAyQTdyMR?=
HT-29  NFXkfYtCeG:ydH;zbZMhSXO|YYm= NGLLTGkydU1? NIrBd|Q1QGh? NIXzeHZFVVOR MX7lcohidmOnczDic5J1\XqxbXniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> NX7GW5FIOjR6NEKxOVg>
Microglia  MoPXRZBweHSxc3nzJGF{e2G7 M3S3dlVuVQ>? NXzBdZJ4OjSq MV;k[YNz\WG|ZYOgbJlxd3irYT3pcoR2[2WmIHPlcIwh\GWjdHi= NVi2bolTOjR6MUi2NFE>
A2780cp MY\BdI9xfG:|aYOgRZN{[Xl? MVGyMlVuVQ>? NFfwbJYycA>? M3PPXIRlUDKR MV;lcohidmOnczDjbZNxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo NXfHOnlOOjR6MUe5OFY>
HepG2 NGLJWmhHfW6ldHnvckBCe3OjeR?= M3TV[VVuVQ>? NVL4[4RZPGh? MVXpcoNz\WG|ZYOgTGwhemWuZXHz[S=> M3PCfFI1PzF|NUi3
A549 NVH4cHJuSXCxcITvd4l{KEG|c3H5 M{SwT|VuVQ>? MVm0PIg> MWTk[YNz\WG|ZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdCCmZXH0bEBidmRiZYjwdoV{e2mxbjDs[ZZmdHNib3[gZ4F{eGG|ZT2zMEBD\WOuaX6tNUBidmRiTFOzMWlK MkO2NlQ4ODZ|MEO=
U2OS Mlz1RZBweHSxc3nzJGF{e2G7 M4HxWFExdU1? NIO4bokzPGh? NIDyfXdqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h? Ml\6NlQ3OzlyMUO=
Saos-2 M{nuXGFxd3C2b4Ppd{BCe3OjeR?= M{XublExdU1? MW[yOIg> Mn;TbY51\W6|aX\p[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJJRp\SCXMl;TJINmdGy|IHnu[JVk\WRiYomgSI95 MnLsNlQ3OzlyMUO=
A549 M2HWOGFxd3C2b4Ppd{BCe3OjeR?= NVHubI16OTCvTR?= NHy3S2E1QGh? NX3uZ4J[[WOlZXzldoF1\XNidHjlJJJm\HWldHnvckBw\iClZXzsJJZq[WKrbHn0fUBqdmS3Y3XkJIJ6KFCWWB?= Mn\qNlQ3OjZ5MkK=
HCT116  M1LTO2Fxd3C2b4Ppd{BCe3OjeR?= M2OxdFVuVQ>? MUKyOIg> MlrB[Y5p[W6lZYOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHHwbYdmdmmw NYfhZlBxOjR4Mk[1NlI>
HGC-27 MVHGeY5kfGmxbjDBd5NigQ>? NGjrNmUyOG2P M4f5TVFp M37QfYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBtd3O|IHL5JHJCTDByMTDvdkBOUy1{MkC2 MnLZNlQ1OTZ|NEm=
U2OS  NYH2WZpmTnWwY4Tpc44hSXO|YYm= MVywMlUwOW2P MnvpOFhp MXXpcoR2[2W|IIPhcIlvd227Y3nuMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> NUfrWZVTOjR|NUizOFI>
MG-63 NHzYcWlHfW6ldHnvckBCe3OjeR?= MV2wMlUwOW2P MkjmOFhp MWfpcoR2[2W|IIPhcIlvd227Y3nuMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> MVOyOFM2QDN2Mh?=
MG-63 NXTYd4xwSXCxcITvd4l{KEG|c3H5 NWXwe|lIOC53L{HtUS=> NIq1[oQ{Omh? M4rUVoVvcGGwY3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDDhdI9xfG:|aYO= NWXITGNjOjR|NUizOFI>
MG-63 NEX3SpJCeG:ydH;zbZMhSXO|YYm= M1vZ[FExdU1? M2m0UlEzcA>? NWTOcWNl\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? MnTTNlQ{PTh|MEG=
NTUB1 MnniRZBweHSxc3nzJGF{e2G7 NYfRVHlDPW2P MWCxMlVp NYXGTlVoeG:2ZX70bYF1\XNiY3Xs[YNwgGmkLXnu[JVk\WRiYYDvdJRwe2m| MofMNlQ{PDlzN{[=
T24 M1zUSmFxd3C2b4Ppd{BCe3OjeR?= M{PCblVuVQ>? MmrENU42cA>? NYXrOJlKeG:2ZX70bYF1\XNiY3Xs[YNwgGmkLXnu[JVk\WRiYYDvdJRwe2m| MnjaNlQ{PDlzN{[=
SGC-7901  NVPJTWRESXCxcITvd4l{KEG|c3H5 M4fK[|JuVQ>? NWC4VoJwOWh? M1vwSYlv[3KnYYPld{BESS12IHnu[JVk\WRiYYDvdJRwe2m| NV\WTXVmOjR|MkGzOFA>
SMMC-7721 NUXnco56SXCxcITvd4l{KEG|c3H5 NFLVNnozdU1? MVqxbC=> M2Dp[4lv[3KnYYPld{BESS12IHnu[JVk\WRiYYDvdJRwe2m| NVzOU2xbOjR|MkGzOFA>
ECSCs  M1u4b2Fxd3C2b4Ppd{BCe3OjeR?= M3X6TlExdU1? NF[wUpo1cA>? NXv1bndG\GWlcnXhd4V{KHKjcHHtfYNqdi22cnXheIVlKGGyb4D0c5Nqew>? M1y0eFI1OzF7MUC5
MCF-7  M4DobGZ2dmO2aX;uJGF{e2G7 MYOxNI1O MWWyOIg> MUHpcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JIRzfWe| NEnhRlYzPDNzNUW3PC=>
UOK257 MkD2RZBweHSxc3nzJGF{e2G7 M{nuZ|VuVQ>? MoXaN4g> Mn;E[Y5p[W6lZYOgdIFkdGm2YYjlcE1u\WSrYYTl[EBieG:ydH;zbZPDqA>? MV2yOFMxPTZyNB?=
ACHN-5968 NGezXGJCeG:ydH;zbZMhSXO|YYm= Mo\ROY1O MmLTN4g> Mn;Z[Y5p[W6lZYOgdIFkdGm2YYjlcE1u\WSrYYTl[EBieG:ydH;zbZPDqA>? NEHQRYwzPDNyNU[wOC=>
Huh7 NX\BTHRpSXCxcITvd4l{KEG|c3H5 NGPpdpIzdU1? MXixNog> MomySG1UVw>? M2j4OIlvcGmkaYTzJGFbTDhyNUWtbY5lfWOnZDDj[YxtKGSnYYTo MnvhNlQzQTd|MEC=
Hep3B M1rHXGFxd3C2b4Ppd{BCe3OjeR?= NGHNXXgzdU1? NF;X[HMyOmh? MYrEUXNQ MWnpcohq[mm2czDBXmQ5ODV3LXnu[JVk\WRiY3XscEBl\WG2aB?= NUC4bZFqOjR{OUezNFA>
RKO NWmyVGozTnWwY4Tpc44hSXO|YYm= MWiycW0> NXe0OZo4OWh? NUnvVXRYTE2VTx?= MmTV[Y5p[W6lZYOgZ4VtdCCmZXH0bEBjgSCpZXzkZY5idXmlaX6= M13Dd|I1OjlzN{e3
HepG2 E47 M4XjeWZ2dmO2aX;uJGF{e2G7 NXTVPXZrOi53bV2= M1:0WFQ5cA>? NXTVO|NRcW6lcnXhd4V{KHSqZTD0c5hq[2m2eTDv[kBCSSxiQmPPMEBidmRiQ1PsOC=> NUDVUHVSOjR{N{O3N|g>
LoVo  M3PTUWFxd3C2b4Ppd{BCe3OjeR?= MVW1cW0> NXroRZBmPDiq NHvWPIFmdmijbnPld{BFS0FvaX7keYNm\CCjcH;weI9{cXNw MX:yOFIxOThzMh?=
WiDr NGHNZpdHfW6ldHnvckBCe3OjeR?= NXmy[XZEOTCvTR?= NFf1eVIycA>? MkLubY5pcWKrdIOgVGNDVC2rbnT1Z4VlKEyFMzDJTUBmgHC{ZYPzbY9v NULMe45rOjRzOUC0PFk>
H1299  M37sUmZ2dmO2aX;uJGF{e2G7 MX2xNI1O NFrNTHE1cA>? NVXMNW5lcW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? NUD4VGQ3OjRzN{OyNFg>
H460 MX7GeY5kfGmxbjDBd5NigQ>? NEHm[3UyOG2P M1jHflRp NXz2WFE3cW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? MU[yOFE4OzJyOB?=
A549 Mn76SpVv[3Srb36gRZN{[Xl? NETufpcyOG2P MWS0bC=> NYDidVNKcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliaYLyZYRq[XSrb36= MWmyOFE1Ojd|NR?=
Hep3B MlnuRZBweHSxc3nzJGF{e2G7 NH\VXGI2dU1? MYKyOIg> NFnJVo1ifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> M{TuO|I1ODZ4Nkmz
SMMC-7721 M{jSNmFxd3C2b4Ppd{BCe3OjeR?= MonYOY1O M4CxbFI1cA>? NXjz[Jlj[XS2ZX71ZZRmeyCWTl[t{tEheHKxdHXjeIlwdiCjZ3HpcpN1KHOncoXtJJN1[XK4YYTpc44udWWmaXH0[YQh[XCxcITvd4l{ NVPKZ2J1OjRyNk[2PVM>
HO8910 NGrPU4pCeG:ydH;zbZMhSXO|YYm= Mom3NVBuVQ>? MmfhNVJp NYnJOFl{\W6qYX7j[ZMhSjF7LXnu[JVk\WRiYYDvdJRwe2l? M1O1SFI{QTh|NkGw
MCF7 NVfh[lV7TnWwY4Tpc44hSXO|YYm= Mk\IOY1O Mnn5NlRp NH62ZmRqdmO{ZXHz[ZMhS3WRIHnu[JVk\WRiY3XscEBl\WG2aB?= M1LPb|I{QTZ{NkK5
HONE-1  M{LMfGZ2dmO2aX;uJGF{e2G7 NV:xTXFGPW2P M{nHSFFp MlzKdoVxemW|c3XzJFZzNW2nZHnheIVlKFKRUzDwdo9lfWO2aX;u MWWyN|g6OjN3OB?=
HeLa NGewSHJHfW6ldHnvckBCe3OjeR?= MW[xNI1O MUGybC=> Mmexd5VxeHKnc4Pld{BNSzNiSVmg[ZhxemW|c3nzc44> NIW2do0zOzh4NEezPC=>
HepG2 NEnrdXdHfW6ldHnvckBCe3OjeR?= MkXJNVBuVQ>? M13YcVI1cA>? MkfabY5pcWKrdIOgd4lVUUeDUj2gZY5lKEiEU2OtbY5lfWOnZDDheZRweGijZ4m= M{n4OFI{QDF5MESw
SH-SY5Y MmLLSpVv[3Srb36gRZN{[Xl? MnTSNY1O M4rGSFI1cA>? NVTPeVNkcW6qaXLpeJMhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JHRQS1B? MkXuNlM4PDNzNEi=
SH-SY5Y NXHvWoNkSXCxcITvd4l{KEG|c3H5 Mn7GOY1O NYjkS2JoOWh? NVTyO405[WKxbHnzbIV{KGOnbHHzeJJwdCCwZYXyc5Bzd3SnY4TpeoUh\W[oZXP0 NXLwelJKOjN4MUmzPVU>
PC12  NWrLU3Y4TnWwY4Tpc44hSXO|YYm= NHTIOlgyOG2P NELjfpUzPGh? NWHrTWJvf2G2ZYK= M{XwR:KhcW6qaXLpeJMh[2i7bX;0dplxe2mwLXzpb4UheHKxdHXhd49u[WxiYXP0bZZqfHlw M3jMbFI{PjB|OUe5
OV2008 MWLBdI9xfG:|aYOgRZN{[Xl? NUnZbnpMPW2P NGXIVGwzPGh? NH\qN5Jkd264ZYL0d{BHXFl5MkCge4l1cCCFRFTQJIlvfG9iYX6gZYRlcXSrdnWg[YZn\WO2IITve4Fz\HNia3nscIlv\yCxdnHybYFvKGOjbnPldkBk\Wyucx?= M{HVZVI{PTl{Mkix
A2780 MVHBdI9xfG:|aYOgRZN{[Xl? MoXWOY1O MXyyOIg> NX;nNndX[2:wdnXyeJMhTlS\N{KwJJdqfGhiQ1TEVEBqdnSxIHHuJIFl\Gm2aY\lJIVn\mWldDD0c5diemS|IHvpcIxqdmdib4\hdolidiClYX7j[ZIh[2WubIO= M4XkeFI{PTl{Mkix
Saos-2  NFH4RohCeG:ydH;zbZMhSXO|YYm= NFPCVZIydU1? M2nYOlk3cA>? NV7VVmNocW6lcnXhd4V{KGOnbHyg[IVifGhiaX7keYNm\CCkeTDQR3g> MYqyN|U3OzF5MR?=
1321N1 MYLDfZRwfG:6aXPpeJkhSXO|YYm= MnmwOY1O MmTYNlRp MVzwdo91\WO2czDj[YxtKGGpYXnud5QhWEOQLXnu[JVk\WRidH;4bYNqfHl? MWmyN|UzPTJ4NR?=
SH-SY5Y MXjDfZRwfG:6aXPpeJkhSXO|YYm= NUPP[HJbPW2P MmC5NlRp NYe2UlJVcW6lcnXhd4V{KFCFTjD0c5hq[2m2eR?= M2DFTVI{PTJ3Mk[1
HT-29  MVfGeY5kfGmxbjDBd5NigQ>? NHz4cIMydU1? MkPmOFgwQT[q NUTlbVBXcW6qaXLpeJMhSU2SSzDpcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> MX6yN|UxQDJ5Mh?=
OR6 NG\ndWVHfW6ldHnvckBCe3OjeR?= NX23doU4OTCvTR?= MmDoO|Jp M3ntcZN2eHC{ZYPz[ZMhUEOYIILldIxq[2G2aX;uJIFv\CCob4LtZZRqd25ib3[gZZV1d3CqYXfvd49u\XN? NXfXd3UyOjN|OUW4O|U>
Hela  NWm3O3h6TnWwY4Tpc44hSXO|YYm= M2TuclVuVQ>? MWmyOIg> MmfZbY5pcWKrdIOgd5Rien[jdHnvck1qdmS3Y3XkJIF2fG:yaHHnfS=> NUTSRYFjOjN|OUW2O|k>
MCF-7  NFnaUJlHfW6ldHnvckBCe3OjeR?= NUC1V5dqPW2P MViyOIg> MUPpcohq[mm2czDzeIFzfmG2aX;uMYlv\HWlZXSgZZV1d3CqYXf5 MX2yN|M6PTZ5OR?=
HUVECs M3qwZ2Z2dmO2aX;uJGF{e2G7 MnfJN41O MmTkNlRp Mor3Zoxw[2u|IITo[UBxem:2ZXP0bZZmKGWoZnXjeEBw\iC{ZYP2[ZJifHKxbDDifUBqdmirYnn0bY5oKGG3dH;wbIFogQ>? MX[yN|M2QDl{OB?=
T24 NYLrOZU{TnWwY4Tpc44hSXO|YYm= MWOxNI1O NUT3[YJbOWh? MlvjdoVlfWOnczD0bIUh[2ynYY\h[4Uhd2ZiTFOzJIFnfGW{IHLhbYNidGmwIITy[YF1dWWwdB?= M3\RWFI{OzV2MEiw
U251MG  MWfGeY5kfGmxbjDBd5NigQ>? NF7XblY{dU1? NV2wSZp4OWh? NEHifGh{fXCycnXzd4V{KEyFMz3JTUBxem:2ZXnuJIV5eHKnc4Ppc44> M3npNlI{OzN6NkG4
GTL-16  Mn;vRZBweHSxc3nzJGF{e2G7 M{PDOlVuVQ>? M4O4dVI1cA>? NF;aUodz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHzJINwdXCjcnXkJJRwKGOnbHzzJJRz\WG2ZXSge4l1cCCPRWSgbY5pcWKrdH;ydy=> MWiyN|MyOzR7MB?=
T-47D M{n0XWZ2dmO2aX;uJGF{e2G7 MUmxNI1O MWSybC=> MmnnbY5pcWKrdIOgZZV1d3CqYXf5JJBzd2Onc4OgZY5lKGmwY4LlZZNmeyC{YYDhcZlkcW5iaX7keYNm\CCjcH;weI9{cXN? NEjwPGEzOzNyMECyOi=>
PaCa44 M17OU2Fxd3C2b4Ppd{BCe3OjeR?= M{DoV|IvPW2P M1fXZlFp MnHMdoVlfWOnc9Mg[4VvcXCrbj3t[YRq[XSnZDDhdI9xfG:|aYO= MXeyN|EzPDFzMh?=
MDA-MB231 NWXOeVlxTnWwY4Tpc44hSXO|YYm= M{\lcFVuVQ>? MX:xbC=> NVHYe5ZFcW6lcnXhd4V{KHKnc4\ldoF1em:uLX3l[IlifGWmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>? M4PMelI{ODh6OEWw
HeLa Mor0RZBweHSxc3nzJGF{e2G7 MYKxNI1O MoK0Nog> MlrZ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHPvMZRz\WG2bXXueEB4cXSqIGDFTS=> Ml3aNlMxODBzM{W=
SK-HEP-1 NU\kSJRvSXCxcITvd4l{KEG|c3H5 M4HO[FExdU1? Ml\ZNYg> NVfmUVM4eHKxdHXjeJMh[WejaX7zeEBifXSxcHjh[5kh[W6mIHnu[JVk\XNiYYDvdJRwe2m|IHnuJIJ2\mGuaX6teJJm[XSnZDDj[Yxtew>? NVnvUZhIOjJ6NUi2OFk>
HepG2 M{TLbmFxd3C2b4Ppd{BCe3OjeR?= MYCzcW0> M4e3NFVp M1PuVpJm\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDRSJM> Mn65NlI5OzZ3OUW=
MCF-7  NEnBSlJHfW6ldHnvckBCe3OjeR?= Mo[wNo1O M{HqbFI1cA>? NWTDfYNIcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> NF7qUJgzPDl5ME[3Oi=>
MDA-MB-231 NHryUoZHfW6ldHnvckBCe3OjeR?= MlzFNo1O MoH2NlRp NXLSdYxGcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> NV3SZ|dGOjR7N{C2O|Y>
MCF-7  NH\ENpNHfW6ldHnvckBCe3OjeR?= NWXI[2NLOm2P M1y1bVQ5cA>? MnPTdJJwdW:2ZYOgWG0ucW6mdXPl[EBk\WyuIHTlZZRp NYXSZ45qOjR7N{C2O|Y>
MDA-MB-231 NXrpeYVzTnWwY4Tpc44hSXO|YYm= NXHqPGNMOm2P NGfqZlE1QGh? NFmxRmdxem:vb4Tld{BVVS2rbnT1Z4VlKGOnbHyg[IVifGh? NFSwd4YzPDl5ME[3Oi=>
PANC-1  MlznRZBweHSxc3nzJGF{e2G7 NHzQPHkydU1? Mne3OFhp NYnzdoM1TE2VTx?= M4G2UIVvcGGwY3XzJIJwenSnen;tbYIucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDsc5N{ NWrDVndNOjR6NEKxOVg>
MDA-MB 231 NF6zSINCeG:ydH;zbZMhSXO|YYm= M4K4c|VuVQ>? MYqwMlVp Ml7DcY9lfWyjdHXzJHRw[2:vaX9CsuKhcW6mdXPl[EBieG:ydH;zbZM> MoTTNlQ5OzB5OEG=
Microglia  NVLXVJk3SXCxcITvd4l{KEG|c3H5 M1XzN|VuVQ>? MmW2NlRp M2Dmc4Rm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MVKyOFgyQDZyMR?=
A2780cp M1:xWGFxd3C2b4Ppd{BCe3OjeR?= MYSyMlVuVQ>? MlXYNYg> NWfXUIt2\GSKMl:= NX;Nb|do\W6qYX7j[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? MnPTNlQ5OTd7NE[=
HepG2 NYDReY05TnWwY4Tpc44hSXO|YYm= M2\DNFVuVQ>? M{LnW|Rp NFHhbYpqdmO{ZXHz[ZMh[2WubIXsZZIhdGW4ZXzzJI9nKEiOwrC= MVyyOFcyOzV6Nx?=
U2OS MmHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPvVlJFOTCvTR?= NFrJfW4zPGh? MULpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25iaX7keYNm\CCkeTDEc5g> M331UlI1PjN7MEGz
HCT116 MYPBdI9xfG:|aYOgRZN{[Xl? NUPXfYN1PW2P MoLkNlRp M1PL[2ROW09? M3m1cIVvcGGwY3XzJIFxcWenbnnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M2LQZVI1PjJ4NUKy
MCF-7  NXjJWGt[SXCxcITvd4l{KEG|c3H5 Mmi5NE4ydU1? NFPFTXU3cA>? NFuxNnVmdmijbnPld{B{cXK2aX7vcE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MlHMNlI4PTF7OEm=
PC-3  NIDRbnFCeG:ydH;zbZMhSXO|YYm= MYKycW0> NXThcldCOmh? MlrubY5kemWjc3XzJG9TUS2rbnT1Z4VlKGOnbHyg[IVifGh? Ml\vNlI4PDV3OEC=
U251  M{D3fGFxd3C2b4Ppd{BCe3OjeR?= NInaTpA2dU1? NInXeJkzPGh? M3f6Xolv[3KnYYPld{BUOS2rbnT1Z4VlKGOnbHyg[IVifGh? MnnsNlI2Pzl5OEi=
HeLa  MmLpRZBweHSxc3nzJGF{e2G7 M1PoVVVuVQ>? NXXpXnoyOjSq NEHuVXhqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JINmdGxiZHXheIg> M3myW|IzPTR3MUK4
A549 M3jubGZ2dmO2aX;uJGF{e2G7 NHe3[IgxNjGvTR?= MWGyOIg> MmHqd5VxeHKnc4Pld{BUXTFzMke0MYlv\HWlZXSgZ4VtdCCmZXH0bC=> MnfDNlI1PjZ7NkC=
pDCs NEjIRVlHfW6ldHnvckBCe3OjeR?= NInUS5cyOG2P MnvTNE42cA>? M2T1S:KhemWmdXPld{B1cGViaX7keYN1cW:wIH;mJGlHVi4QsTDifUB{e1KQQUSw MUWyNlM6PjV7OR?=
BGC-823 MmnGSpVv[3Srb36gRZN{[Xl? NG[yPVg2dU1? Ml2yNog> MljmbY5pcWKrdIOgeIhmKHKjdHWgc4Yh[XW2b4DoZYdq[yClZXzsdy=> NHi3SJYzOjN{MkG1Ni=>
U937 NWHUPYtxTnWwY4Tpc44hSXO|YYm= NFfxWlkzdU1? M4m4XlEzcA>? NGfVfJZl\WO{ZXHz[ZMhfGinIHH1eI9xcGGpeTDyZZRqd8Li NUnwbIFoOjJzNUWxOVA>
Marc-145 M{HhS2Z2dmO2aX;uJGF{e2G7 MV21cW0> M{LtelEzNzJ2L{O2bC=> NHzDeHZz\WS3Y3XzJJRp\SCSUmLTWkB1cXSncoOgZY5lKHSqZTDwdo91\WmwIHX4dJJme3Orb36= NF;JU4gzOjFzOUmwNC=>
HBx  MYrBdI9xfG:|aYOgRZN{[Xl? MWixNI1O M1q2cFQ5cA>? NIDpdI5FVVOR MX;pcoNz\WG|ZYOgZ4VtdCCmZXH0bC=> MVeyNlAzODB5OB?=
MCF-7 NGLEdJZHfW6ldHnvckBCe3OjeR?= M1XYNVExdU1? NFTqdVM1QGh? NGnOZXVjdG:la4OgZZV1d3CqYXf5JIlv\HWlZXSgZpkh[m:{dHX6c41q[g>? M1LHUlIyQTNzOUO3
RMPI8226  NH3JNINHfW6ldHnvckBCe3OjeR?= MUW1cW0> MkKyNYg> M1PxcZN2eHC{ZYPz[ZMhfGinIHzleoVtKG:oIHH1eI9xcGGpeTD1coRmeiCwdYTybYVvfCCmZYDs[ZRqd25? MlvPNlE6OTV4MkC=
PC12/TetOn NF\BTHRHfW6ldHnvckBCe3OjeR?= MWCwMlEwOW2P M3zDZVE5cA>? M3f4Uoxm[WS|IITvJO6yNXO7bjjXWEkh[WOldX31cIF1cW:wLDD0c5hq[2m2eTygZY5lKG:uaXfvcYVzKG[xcn3heIlwdsLi NWLo[ppxOjF7ME[2OVk>
HeLa  NYrRXo9RS3m2b4TvfIlkcXS7IFHzd4F6 M{PhUFJuVQ>? NGq4OHgzPGh? MVLpcohq[mm2ZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kB{cWyrYnnubY4hfG9iSHXMZUBk\Wyucz6= MkL4NlE5PzV|OEW=
Jurkat NFPNSI5HfW6ldHnvckBCe3OjeR?= NVzXR|E6OTCvTR?= NFWzPW4ycA>? NXiySnA4\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEyFMz3JTUBidmRidHjlJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> NHL0O3UzOTh4NECzOy=>
K562 NHTMcpZHfW6ldHnvckBCe3OjeR?= M3HNW|ExdU1? M2Dz[FFp MorN[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGxEOy2LSTDhcoQhfGinIH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= NXm2Snp{OjF6NkSwN|c>
Nara-H M3jrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[1cW0> M{XqfFQ5cA>? NUHCZ5Z6\W6qYX7j[ZMhfGWvc3nyc4xqdXW|bXXkbYF1\WRic4XwdJJme3Orb36gc4YhVmG{YT3IJINmdGxicILvcIln\XKjdHnvci=> NEfqVYUzOThyNUCzNy=>
HUVECs MmDiSpVv[3Srb36gRZN{[Xl? MV[xNI1O NUX1R3RxOC53aB?= Mk[4[IVkemWjc3XzJJRp\SCDR1WtRnNCcW6mdXPl[EBifXSxcHjh[5khdGW4ZR?= M1HV[|IyPDZ6NUmy
HepG2 MX7BdI9xfG:|aYOgRZN{[Xl? M1rjTFJuVQ>? NIHN[I8ycA>? NIDnU|BmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuIHTlZZRp MYqyNVQ2OzZ7MR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
- Collapse

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
- Collapse
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
- Collapse
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389
Smiles C[N]1C=NC(=C2N=CN=C12)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID